Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1 -Rearranged Lung Cancer

Open access
Drilon, Alexander, Somwar, Romel, Wagner, Jacob P., Vellore, Nadeem A., Eide, Christopher A., Zabriskie, Matthew S., Arcila, Maria E., Hechtman, Jaclyn F., Wang, Lu, Smith, Roger S., Kris, Mark G., Riely, Gregory J., Druker, Brian J., O'Hare, Thomas, Ladanyi, Marc, Davare, Monika A.·2016·Clinical Cancer Research

Abstract

Purpose: Rearranged ROS1 is a crizotinib-sensitive oncogenic driver in lung cancer. The development of acquired resistance, however, poses a serious clinical challenge. Consequently, experimental and clinical validation of resistance mechanisms and potential second-line therapies is essential. Experimental Design: We report the discovery of a novel, solvent-front ROS1D2033N mutation in a patient with CD74-ROS1–rearranged lung adenocarcinoma and acquired resistance to crizotinib. Crizotinib resistance of CD74-ROS1D2033N was functionally evaluated using cell-based assays and structural modeling. Results: In biochemical and cell-based assays, the CD74-ROS1D2033N mutant demonstrated significantly decreased sensitivity to crizotinib. Molecular dynamics simulation revealed compromised crizotinib binding due to drastic changes in the electrostatic interaction between the D2033 residue and crizotinib and reorientation of neighboring residues. In contrast, cabozantinib binding was unaffected by the D2033N substitution, and inhibitory potency against the mutant was retained. Notably, cabozantinib treatment resulted in a rapid clinical and near-complete radiographic response in this patient. Conclusions: These results provide the first example of successful therapeutic intervention with targeted therapy to overcome crizotinib resistance in a ROS1-rearranged cancer. Clin Cancer Res; 22(10); 2351–8. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-2013

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 166

Metadata

Authors
Drilon, A., Somwar, R., Wagner, J. P., Vellore, N. A., Eide, C. A., Zabriskie, M. S., Arcila, M. E., Hechtman, J. F., Wang, L., Smith, R. S., Kris, M. G., Riely, G. J., Druker, B. J., O'Hare, T., Ladanyi, M., & Davare, M. A.
Venue
Clinical Cancer Research
Published
2016-05-12
Volume
22
Issue
10
Pages
2351-2358
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2212897984
Cited by
166
References
5
FWCI
13.80
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1 -Rearranged Lung Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-2013
The paper
Drilon, A., Somwar, R., Wagner, J. P., Vellore, N. A., Eide, C. A., Zabriskie, M. S., Arcila, M. E., Hechtman, J. F., Wang, L., Smith, R. S., Kris, M. G., Riely, G. J., Druker, B. J., O'Hare, T., Ladanyi, M., & Davare, M. A. (2016). A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1 -Rearranged Lung Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-2013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.